Welcome to our dedicated page for BriaCell Therapeutics news (Ticker: BCTXW), a resource for investors and traders seeking the latest updates and insights on BriaCell Therapeutics stock.
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company based in Los Angeles. They specialize in developing targeted and safe immunotherapy approaches for cancer management, with a current focus on breast cancer. The company has seen success with their patented 'BriaVax' vaccine in FDA Phase I studies, showing promising results. BriaCell is gearing up for a Phase I/II study to broaden the application of their vaccine technology. They are also working on Bria-OTS, personalized immunotherapy for advanced-stage breast cancer.
BriaCell Therapeutics Corp. (Nasdaq: BCTX) reports significant progress in its Phase 2 study of the Bria-IMT™ regimen for metastatic breast cancer. A patient with ADC-resistant cancer showed a 9.1-month progression-free survival (PFS), quadrupling the PFS of similar studies. This patient, who had failed 8 prior treatments, experienced a marked reduction in tumor size, including the disappearance of a temporal lobe lesion.
The company's President and CEO, Dr. William V. Williams, expressed optimism about replicating these results in their ongoing Phase 3 study. Dr. Giuseppe Del Priore, Chief Medical Officer, highlighted the treatment's favorable safety and tolerability profile. This development represents a potential breakthrough in treating metastatic breast cancer, an area with significant unmet medical needs.
BriaCell Therapeutics presented promising clinical efficacy data for its lead candidate, Bria-IMT™, at the ASCO 2024 meeting. The therapy showed a significant increase in Progression-Free Survival (PFS) and Clinical Benefit Rate (CBR) compared to historical treatments. The therapy was well-tolerated with no related discontinuations. The Phase 2 study included 54 heavily pretreated metastatic breast cancer patients, showing a median PFS of 4.1 months, nearly double the rate of similar studies. Dr. Saranya Chumsri and Dr. Carmen Calfa highlighted the potential for Bria-IMT™ to address unmet medical needs in advanced breast cancer. Further, BriaCell's pivotal Phase 3 study will compare Bria-IMT™ with Treatment of Physician's Choice (TPC).
BriaCell Therapeutics (NASDAQ: BCTX, BCTXW; TSX: BCT), a clinical-stage biotechnology company, has initiated a first-in-human Phase 1/2 study for its immunotherapy, Bria-OTS™, targeting advanced metastatic breast cancer. The study aims to evaluate the safety and efficacy of Bria-OTS™ both as a monotherapy and in combination with the PD-1 inhibitor tislelizumab. This milestone follows the successful completion of Institutional Review Board (IRB) and Clinical Trial Site Agreement (CTA) processes, along with FDA authorization for Investigational New Drug (IND) filings. BriaCell's leadership believes the personalized approach of Bria-OTS™ could lead to more potent and durable responses, potentially improving patients' quality of life and extending survival. The treatment's off-the-shelf nature is expected to provide rapid therapeutic intervention, important for patients with advanced metastatic breast cancer.
BriaCell Therapeutics has announced a clinical supply agreement with BeiGene to assess the safety and efficacy of BriaCell’s Bria-OTS™ immunotherapy in combination with BeiGene's anti-PD-1 antibody, tislelizumab, for treating advanced, heavily pretreated metastatic breast cancer. This Phase 1/2 trial will initially focus on Bria-OTS™ alone in breast cancer, expanding to a combination therapy with tislelizumab. BriaCell aims to extend this therapy to prostate and other cancers. The Bria-OTS™ platform builds on Bria-IMT™, which has shown benefits in patients with CNS metastases and resistance to checkpoint inhibitors and ADCs.
BriaCell Therapeutics announced promising clinical data for its lead product candidate, Bria-IMT™, at the ASCO 2024 Annual Meeting. Key results include a median progression-free survival (PFS) of 4.1 months in ADC-resistant advanced breast cancer patients, which is double the PFS of patients in similar studies. The clinical benefit rate was 55% across HR+, HER2+, and TNBC disease types. Additionally, the therapy achieved an 83% intracranial objective response rate in patients with CNS metastases. The treatment was well-tolerated with no related discontinuations or cases of interstitial lung disease. These findings will be presented through various sessions during the ASCO event held from May 31 to June 4, 2024.
BriaCell Therapeutics, a clinical-stage biotech firm, has closed a $5.0 million registered direct offering with institutional and existing investors, including a director. The offering involves the sale of 2,402,935 common shares and warrants, with each unit priced at $2.00 to $2.215. The proceeds will fund working capital, R&D, a Phase 3 breast cancer study, and legal costs. A.G.P./Alliance Global Partners acted as the sole placement agent. The offering has been conducted under an existing shelf registration statement filed with the SEC.
BriaCell Therapeutics announced a $5.0 million registered direct offering, involving the sale of 2,402,935 common shares or pre-funded warrants and warrants to institutional investors and a director. The shares are priced at $2.00 each for institutional investors and $2.215 for the director, with warrants exercisable at $2.11 within six months and expiring in five years. The proceeds will support working capital, R&D, including a Phase 3 study in advanced breast cancer, and potential share repurchases. The offering closes around May 17, 2024, subject to customary conditions.
FAQ
What is BriaCell Therapeutics Corp focused on?
What is the significance of BriaVax vaccine?
What upcoming clinical trial is BriaCell preparing for?
What is Bria-OTS and its purpose?
Where is BriaCell Therapeutics Corp headquartered?
How can I contact BriaCell for more information?
Who is the Media Relations contact for BriaCell?
How can investors get in touch with BriaCell?
What type of clinical trial is BriaCell conducting for breast cancer?